Mereo BioPharma Gets Second Nasdaq Delisting Notice, Compliance Deadline Extended to Feb 2027
MREO sits 51% above its 52-week low of $0.2 on light trading volume (0.2× avg).
Summary
Mereo BioPharma received a second Nasdaq delisting notice, extending its compliance deadline to February 16, 2027. The stock trades at $0.302, well below the $1.00 minimum bid price.
Key Events · Legal and Risk Events · MREO
-
Second Nasdaq Delisting Notice
On August 18, 2026, Mereo received a second notice from Nasdaq stating it has not regained compliance with the $1.00 minimum bid price requirement.
-
Extended Compliance Deadline
The company now has until February 16, 2027 to achieve a closing bid price of at least $1.00 for 10 consecutive business days.
-
Current Price Far Below Threshold
Mereo's ADSs trade at $0.302, requiring a more than 3x increase to reach the $1.00 minimum bid price.
-
Delisting Risk
If compliance is not regained by the deadline, Nasdaq will issue a delisting notice, though the company may appeal to a Hearings Panel.
Analysis · MREO · Life Sciences
A second Nasdaq notice has been issued to Mereo BioPharma, confirming the company still falls short of the $1.00 minimum bid price requirement. The deadline to regain compliance is now February 16, 2027, but with ADSs trading at $0.302, the gap remains wide. Failure to meet the threshold would trigger delisting, severely curtailing liquidity and investor access. This represents a critical governance and listing risk.
At the time of this filing, MREO was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50M. The 52-week trading range was $0.20 to $2.37. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.